Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review

Erin F. Barreto, Andrew D Rule, Mohammad H Murad, Kianoush B. Kashani, John C Lieske, Patricia J. Erwin, James M. Steckelberg, Ognjen Gajic, Joel M Reid, Sandra L. Kane-Gill

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Serum cystatin C has been proposed as a kidney biomarker to inform drug dosing. We conducted a systematic review to synthesize available data for the association between serum cystatin C and drug pharmacokinetics, dosing, and clinical outcomes in adults (≥18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Scopus were systematically searched from 1946 to September 2017 to identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded. Also, studies were excluded if drug concentrations were unavailable and if a reference standard for drug dosing (eg, serum creatinine) was not concurrently reported. The outcomes of interest included drug clearance (L/h), concentrations (mg/L), target level achievement (%), therapeutic failure (%), and drug toxicity (%). We included 28 articles that evaluated 16 different medications in 3455 participants. Vancomycin was the most well-studied drug. Overall, cystatin C–based estimated glomerular filtration rate (eGFRCystatin C) was more predictive of drug levels and drug clearance than eGFRCreatinine. In only one study were target attainment and outcomes compared between 2 drug-dosing regimens, one based on eGFRCreatinine-Cystatin C and one dosed with the Cockcroft-Gault creatinine clearance equation. Compared with eGFRCreatinine, use of eGFRCystatin C to predict elimination of medications via the kidney was as accurate, if not superior, in most studies, but infrequently were data on target attainment or clinical outcomes reported. Drug-specific dosing protocols that use cystatin C to estimate kidney function should be tested for clinical application.

Original languageEnglish (US)
JournalMayo Clinic Proceedings
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Cystatin C
Creatinine
Pharmaceutical Preparations
Kidney
Acute Kidney Injury
Serum
Renal Elimination
Cystatins
Vancomycin
Drug-Related Side Effects and Adverse Reactions
Glomerular Filtration Rate
PubMed
MEDLINE
Pharmacokinetics
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine : A Systematic Review. / Barreto, Erin F.; Rule, Andrew D; Murad, Mohammad H; Kashani, Kianoush B.; Lieske, John C; Erwin, Patricia J.; Steckelberg, James M.; Gajic, Ognjen; Reid, Joel M; Kane-Gill, Sandra L.

In: Mayo Clinic Proceedings, 01.01.2019.

Research output: Contribution to journalArticle

@article{71bd5d8d5304424d990b476b6b5ffed6,
title = "Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review",
abstract = "Serum cystatin C has been proposed as a kidney biomarker to inform drug dosing. We conducted a systematic review to synthesize available data for the association between serum cystatin C and drug pharmacokinetics, dosing, and clinical outcomes in adults (≥18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Scopus were systematically searched from 1946 to September 2017 to identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded. Also, studies were excluded if drug concentrations were unavailable and if a reference standard for drug dosing (eg, serum creatinine) was not concurrently reported. The outcomes of interest included drug clearance (L/h), concentrations (mg/L), target level achievement ({\%}), therapeutic failure ({\%}), and drug toxicity ({\%}). We included 28 articles that evaluated 16 different medications in 3455 participants. Vancomycin was the most well-studied drug. Overall, cystatin C–based estimated glomerular filtration rate (eGFRCystatin C) was more predictive of drug levels and drug clearance than eGFRCreatinine. In only one study were target attainment and outcomes compared between 2 drug-dosing regimens, one based on eGFRCreatinine-Cystatin C and one dosed with the Cockcroft-Gault creatinine clearance equation. Compared with eGFRCreatinine, use of eGFRCystatin C to predict elimination of medications via the kidney was as accurate, if not superior, in most studies, but infrequently were data on target attainment or clinical outcomes reported. Drug-specific dosing protocols that use cystatin C to estimate kidney function should be tested for clinical application.",
author = "Barreto, {Erin F.} and Rule, {Andrew D} and Murad, {Mohammad H} and Kashani, {Kianoush B.} and Lieske, {John C} and Erwin, {Patricia J.} and Steckelberg, {James M.} and Ognjen Gajic and Reid, {Joel M} and Kane-Gill, {Sandra L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.mayocp.2018.08.002",
language = "English (US)",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",

}

TY - JOUR

T1 - Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine

T2 - A Systematic Review

AU - Barreto, Erin F.

AU - Rule, Andrew D

AU - Murad, Mohammad H

AU - Kashani, Kianoush B.

AU - Lieske, John C

AU - Erwin, Patricia J.

AU - Steckelberg, James M.

AU - Gajic, Ognjen

AU - Reid, Joel M

AU - Kane-Gill, Sandra L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Serum cystatin C has been proposed as a kidney biomarker to inform drug dosing. We conducted a systematic review to synthesize available data for the association between serum cystatin C and drug pharmacokinetics, dosing, and clinical outcomes in adults (≥18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Scopus were systematically searched from 1946 to September 2017 to identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded. Also, studies were excluded if drug concentrations were unavailable and if a reference standard for drug dosing (eg, serum creatinine) was not concurrently reported. The outcomes of interest included drug clearance (L/h), concentrations (mg/L), target level achievement (%), therapeutic failure (%), and drug toxicity (%). We included 28 articles that evaluated 16 different medications in 3455 participants. Vancomycin was the most well-studied drug. Overall, cystatin C–based estimated glomerular filtration rate (eGFRCystatin C) was more predictive of drug levels and drug clearance than eGFRCreatinine. In only one study were target attainment and outcomes compared between 2 drug-dosing regimens, one based on eGFRCreatinine-Cystatin C and one dosed with the Cockcroft-Gault creatinine clearance equation. Compared with eGFRCreatinine, use of eGFRCystatin C to predict elimination of medications via the kidney was as accurate, if not superior, in most studies, but infrequently were data on target attainment or clinical outcomes reported. Drug-specific dosing protocols that use cystatin C to estimate kidney function should be tested for clinical application.

AB - Serum cystatin C has been proposed as a kidney biomarker to inform drug dosing. We conducted a systematic review to synthesize available data for the association between serum cystatin C and drug pharmacokinetics, dosing, and clinical outcomes in adults (≥18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Scopus were systematically searched from 1946 to September 2017 to identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded. Also, studies were excluded if drug concentrations were unavailable and if a reference standard for drug dosing (eg, serum creatinine) was not concurrently reported. The outcomes of interest included drug clearance (L/h), concentrations (mg/L), target level achievement (%), therapeutic failure (%), and drug toxicity (%). We included 28 articles that evaluated 16 different medications in 3455 participants. Vancomycin was the most well-studied drug. Overall, cystatin C–based estimated glomerular filtration rate (eGFRCystatin C) was more predictive of drug levels and drug clearance than eGFRCreatinine. In only one study were target attainment and outcomes compared between 2 drug-dosing regimens, one based on eGFRCreatinine-Cystatin C and one dosed with the Cockcroft-Gault creatinine clearance equation. Compared with eGFRCreatinine, use of eGFRCystatin C to predict elimination of medications via the kidney was as accurate, if not superior, in most studies, but infrequently were data on target attainment or clinical outcomes reported. Drug-specific dosing protocols that use cystatin C to estimate kidney function should be tested for clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85060757081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060757081&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.08.002

DO - 10.1016/j.mayocp.2018.08.002

M3 - Article

C2 - 30713050

AN - SCOPUS:85060757081

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

ER -